Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tyra Biosciences, Inc.TYRA · Entity 4680 | Chief Discovery Officer | February 12, 2026 | February 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tyra Biosciences, Inc.
Report date February 12, 2026 · Filed February 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 146,981 |
Ending reported balance
After 2026-02-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-12 · Sale · Disposed 2,128 · Balance 152,853 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F2: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $31.02 to $31.75. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Row 2 · 2026-02-12 · Sale · Disposed 5,872 · Balance 146,981 F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024. F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $32.98 to $33.85. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 5, 2024.
F2: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $31.02 to $31.75. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F3: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $32.98 to $33.85. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 10, 2023 Filed Jul 12, 2023 22:41 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,202 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-042114 · doc4.xml · derivative · entry 7 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,711 Underlying: Common Stock · 1,202 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 22:41 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 1,202 | $16.01 | $19,240.29 |
DisclosureSEC source: 0001209191-23-042114 · doc4.xml · nonDerivative · entry 2 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.12. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| July 10, 2023 Filed Jul 12, 2023 22:41 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 1,202 | $0.61 | $733.22 |
DisclosureSEC source: 0001209191-23-042114 · doc4.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 529,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 03, 2023 Filed Jul 3, 2023 21:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,265 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-040654 · doc4.xml · derivative · entry 10 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,913 Underlying: Common Stock · 4,265 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| July 03, 2023 Filed Jul 3, 2023 21:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 400 | $17.04 | $6,814.00 |
DisclosureSEC source: 0001209191-23-040654 · doc4.xml · nonDerivative · entry 7 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,981 F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $17.02 to $17.05. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| July 03, 2023 Filed Jul 3, 2023 21:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 3,865 | $16.30 | $62,999.89 |
DisclosureSEC source: 0001209191-23-040654 · doc4.xml · nonDerivative · entry 6 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 528,381 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16 to $17. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| July 03, 2023 Filed Jul 3, 2023 21:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 4,265 | $0.61 | $2,601.65 |
DisclosureSEC source: 0001209191-23-040654 · doc4.xml · nonDerivative · entry 5 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 532,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 21:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,819 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-040654 · doc4.xml · derivative · entry 9 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,178 Underlying: Common Stock · 18,819 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 21:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 18,819 | $16.97 | $319,418.65 |
DisclosureSEC source: 0001209191-23-040654 · doc4.xml · nonDerivative · entry 4 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.45 to $17.14. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 30, 2023 Filed Jul 3, 2023 21:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 18,819 | $0.61 | $11,479.59 |
DisclosureSEC source: 0001209191-23-040654 · doc4.xml · nonDerivative · entry 3 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 546,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 21:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,281 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-040654 · doc4.xml · derivative · entry 8 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,997 Underlying: Common Stock · 17,281 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 21:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 17,281 | $16.49 | $285,013.80 |
DisclosureSEC source: 0001209191-23-040654 · doc4.xml · nonDerivative · entry 2 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.13 to $17.09. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 21:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 17,281 | $0.61 | $10,541.41 |
DisclosureSEC source: 0001209191-23-040654 · doc4.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 545,262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2023 Filed Jun 29, 2023 00:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,524 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-040105 · doc4.xml · derivative · entry 11 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 182,278 Underlying: Common Stock · 13,524 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| June 28, 2023 Filed Jun 29, 2023 00:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 13,524 | $16.91 | $228,636.74 |
DisclosureSEC source: 0001209191-23-040105 · doc4.xml · nonDerivative · entry 8 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F6 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.50 to $17.09. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 28, 2023 Filed Jun 29, 2023 00:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 13,524 | $0.61 | $8,249.64 |
DisclosureSEC source: 0001209191-23-040105 · doc4.xml · nonDerivative · entry 7 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 541,505 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 00:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,028 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-040105 · doc4.xml · derivative · entry 10 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 195,802 Underlying: Common Stock · 16,028 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 00:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 8,135 | $17.09 | $139,024.71 |
DisclosureSEC source: 0001209191-23-040105 · doc4.xml · nonDerivative · entry 6 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F5 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $17.02 to $17.20. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 00:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 7,893 | $16.73 | $132,049.89 |
DisclosureSEC source: 0001209191-23-040105 · doc4.xml · nonDerivative · entry 5 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 536,116 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F4 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.01 to $17.01. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 27, 2023 Filed Jun 29, 2023 00:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 16,028 | $0.61 | $9,777.08 |
DisclosureSEC source: 0001209191-23-040105 · doc4.xml · nonDerivative · entry 4 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 544,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 26, 2023 Filed Jun 29, 2023 00:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,232 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-040105 · doc4.xml · derivative · entry 9 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,830 Underlying: Common Stock · 17,232 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| June 26, 2023 Filed Jun 29, 2023 00:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 6,370 | $17.24 | $109,793.32 |
DisclosureSEC source: 0001209191-23-040105 · doc4.xml · nonDerivative · entry 3 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $17.02 to $17.69. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 26, 2023 Filed Jun 29, 2023 00:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 10,862 | $16.49 | $179,131.76 |
DisclosureSEC source: 0001209191-23-040105 · doc4.xml · nonDerivative · entry 2 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 534,351 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 7, 2022. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.01 to $17.005. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 26, 2023 Filed Jun 29, 2023 00:31 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 17,232 | $0.61 | $10,511.52 |
DisclosureSEC source: 0001209191-23-040105 · doc4.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 545,213 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 00:58 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,592 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-037611 · doc4.xml · derivative · entry 9 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 229,062 Underlying: Common Stock · 12,592 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 00:58 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 12,592 | $16.15 | $203,301.62 |
DisclosureSEC source: 0001209191-23-037611 · doc4.xml · nonDerivative · entry 6 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.64. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 00:58 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 12,592 | $0.61 | $7,681.12 |
DisclosureSEC source: 0001209191-23-037611 · doc4.xml · nonDerivative · entry 5 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 540,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 00:58 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 120 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-037611 · doc4.xml · derivative · entry 8 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 241,654 Underlying: Common Stock · 120 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 00:58 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 120 | $16.45 | $1,974.00 |
DisclosureSEC source: 0001209191-23-037611 · doc4.xml · nonDerivative · entry 4 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 00:58 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 120 | $0.61 | $73.20 |
DisclosureSEC source: 0001209191-23-037611 · doc4.xml · nonDerivative · entry 3 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 528,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2023 Filed Jun 16, 2023 00:58 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,628 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-037611 · doc4.xml · derivative · entry 7 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 241,774 Underlying: Common Stock · 5,628 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| June 13, 2023 Filed Jun 16, 2023 00:58 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 5,628 | $16.01 | $90,129.04 |
DisclosureSEC source: 0001209191-23-037611 · doc4.xml · nonDerivative · entry 2 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $16.00 to $16.38. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| June 13, 2023 Filed Jun 16, 2023 00:58 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 5,628 | $0.61 | $3,433.08 |
DisclosureSEC source: 0001209191-23-037611 · doc4.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 533,609 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 00:07 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-022432 · doc4.xml · derivative · entry 9 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 229,421 Underlying: Common Stock · 2,000 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 00:07 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 2,000 | $16.16 | $32,313.80 |
DisclosureSEC source: 0001209191-23-022432 · doc4.xml · nonDerivative · entry 6 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 00:07 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 2,000 | $0.61 | $1,220.00 |
DisclosureSEC source: 0001209191-23-022432 · doc4.xml · nonDerivative · entry 5 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 529,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 00:07 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 400 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-022432 · doc4.xml · derivative · entry 8 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 231,421 Underlying: Common Stock · 400 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 00:07 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 400 | $16.00 | $6,400.24 |
DisclosureSEC source: 0001209191-23-022432 · doc4.xml · nonDerivative · entry 4 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 00:07 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 400 | $0.61 | $244.00 |
DisclosureSEC source: 0001209191-23-022432 · doc4.xml · nonDerivative · entry 3 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 528,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2023 Filed Apr 4, 2023 00:07 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-022432 · doc4.xml · derivative · entry 7 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 231,821 Underlying: Common Stock · 2,000 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| March 30, 2023 Filed Apr 4, 2023 00:07 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 2,000 | $16.01 | $32,015.00 |
DisclosureSEC source: 0001209191-23-022432 · doc4.xml · nonDerivative · entry 2 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. Read SEC document |
| March 30, 2023 Filed Apr 4, 2023 00:07 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 2,000 | $0.61 | $1,220.00 |
DisclosureSEC source: 0001209191-23-022432 · doc4.xml · nonDerivative · entry 1 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 529,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2023 Filed Mar 29, 2023 23:53 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,187 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-021564 · doc4.xml · derivative · entry 9 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 233,821 Underlying: Common Stock · 2,187 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| March 29, 2023 Filed Mar 29, 2023 23:53 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 2,187 | $16.21 | $35,458.71 |
DisclosureSEC source: 0001209191-23-021564 · doc4.xml · nonDerivative · entry 6 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. Read SEC document |
| March 29, 2023 Filed Mar 29, 2023 23:53 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 2,187 | $0.61 | $1,334.07 |
DisclosureSEC source: 0001209191-23-021564 · doc4.xml · nonDerivative · entry 5 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 530,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 28, 2023 Filed Mar 29, 2023 23:53 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,346 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-021564 · doc4.xml · derivative · entry 8 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,008 Underlying: Common Stock · 3,346 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| March 28, 2023 Filed Mar 29, 2023 23:53 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 3,346 | $16.00 | $53,536.00 |
DisclosureSEC source: 0001209191-23-021564 · doc4.xml · nonDerivative · entry 4 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. Read SEC document |
| March 28, 2023 Filed Mar 29, 2023 23:53 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionCommon Stock | 3,346 | $0.61 | $2,041.06 |
DisclosureSEC source: 0001209191-23-021564 · doc4.xml · nonDerivative · entry 3 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 531,327 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 23:53 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,048 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001209191-23-021564 · doc4.xml · derivative · entry 7 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,354 Underlying: Common Stock · 8,048 shares Expires 2031-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on January 27, 2021, and 1/48th of the shares subject to the option vest monthly thereafter. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 23:53 UTC | Tyra Biosciences, Inc. TYRA · Entity 4680 | SaleCommon Stock | 8,048 | $16.00 | $128,768.00 |
DisclosureSEC source: 0001209191-23-021564 · doc4.xml · nonDerivative · entry 2 Bensen Daniel · CIK 0001880946 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 527,981 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in March 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.